POSTER PRESENTATION





Component resolved diagnosis in relation to severity of hazelnut allergy across Europe

MR Datema^{1*}, L Zuidmeer¹, C Garino², J Marsh³, A Lovegrove³, M Clausen⁴, D Gislason⁴, R Dubakiene⁵, I Reig⁶, L Barreales⁶, AC Knulst⁷, T-M Le⁷, ML Kowalski⁸, M Jedvzejczak⁸, J Lidholm⁹, T Kralimarkova¹⁰, T Popov¹⁰, R Asero¹¹, S Seneviratne¹², N Sinaniotis¹³, N Papadopoulos¹³, A Purohit¹⁴, F de Blay¹⁴, P Bures¹⁵, S Vieths¹⁶, M Fernández-Rivas⁶, K Hoffmann-Sommergruber¹⁷, R van Ree¹, B Ballmer-Weber¹⁵

From Food Allergy and Anaphylaxis Meeting (FAAM 2013) Nice, France. 7-9 February 2013

Background

Hazelnut is one of the most common food allergies across Europe although sensitization profiles to specific hazelnut allergens differ between countries. We aim explore geographical differences across Europe regarding molecular sensitization profiles and asses possible associations with severity of hazelnut allergy.

Methods


This study was part of EuroPrevall, a multi-center European study on food allergies. A cohort of 2272 subjects from 12 European countries with reported allergy to at least one of 24 common foods was tested by ImmunoCAP (CAP) and skin prick test (SPT) to a panel of 24 foods, 12 inhalant allergens and latex. Subjects with a convincing history of hazelnut allergy (n=739) were included in this study. Component-resolved diagnosis (CRD) was performed on 426/739 with well-characterized purified recombinant (r) Cor a 1 (Bet v 1-homologue), rCor a 2 (profilin), rCor a 8 (LTP), rCor a 9 (legumin), rCor a 11 (vicilin), nCor a 12 (oleosin), rCor a 14 (2S albumin) and MUXF (CCD). Double-blind placebo-controlled (DBPCFC) food challenges were performed with 128 subjects.

Results

Hazelnut ranked 1st across Europe in an outpatient clinic population, with 739subjects (32.5 %) reporting a convincing clinical history, ranging from 26.4% to 68.6% in Czech Republic, Poland, the Netherlands, France, United Kingdom, Italy, Switzerland and Lithuania and

¹Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands

Full list of author information is available at the end of the article



Conclusion

The outcome of this study so far confirms the results from previous studies. This standardized multinational study provides a unique set of data regarding hazelnut allergy and sensitization profiles.

Disclosure of interest

None declared.

Author details

¹Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands. ²DiSCAFF & Drug and Food Biotechnological Center, Università del Piemonte Orientale, Novara, Italy. ³Rothamsted Research, Harpenden, Hertfordshire, UK. ⁴Landspitali University Hospital, Reykjavík, Iceland. ⁵Vilnius University, Vilnius, Lithuania. ⁶Allergy Department, Hospital Clínico San Carlos, Madrid, Spain. ⁷Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, the Netherlands. ⁸Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland. ⁹Phadia AB, Uppsala, Sweden. ¹⁰Clinical Centre of Allergology, Alexandrovska Hospital, Sofia, Bulgaria. ¹¹Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy. ¹²Department of Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College London, London, UK. ¹³Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece. ¹⁴Division of Allergy, Department of



© 2013 Datema et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Chest Diseases, University Hospitals of Strasbourg, Strasbourg, France. ¹⁵Allergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland. ¹⁶Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany. ¹⁷Department of Pathophysiology, Medical University of Vienna, Vienna, Austria.

Published: 25 July 2013

doi:10.1186/2045-7022-3-S3-P39

Cite this article as: Datema *et al.*: **Component resolved diagnosis in relation to severity of hazelnut allergy across Europe.** *Clinical and Translational Allergy* 2013 **3**(Suppl 3):P39.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit